The use of acyclovir for cytomegalovirus infections in the immunocompromised host
Despite the lack of virus-specified thymidine kinase activity, human cytomegalovirus may be sensitive to acyclovir in vitro at concentrations between 10 and 25 mg/l. The inhibitory effect of acyclovir can be further increased by the presence of small amounts of human alpha or beta interferon. Twenty...
Saved in:
Published in | Journal of antimicrobial chemotherapy Vol. 12 Suppl B; p. 181 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.01.1983
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Despite the lack of virus-specified thymidine kinase activity, human cytomegalovirus may be sensitive to acyclovir in vitro at concentrations between 10 and 25 mg/l. The inhibitory effect of acyclovir can be further increased by the presence of small amounts of human alpha or beta interferon. Twenty-one allogeneic marrow graft recipients with biopsy-proven cytomegalovirus pneumonia were treated with either high doses of acyclovir (eight patients) or the combination of acyclovir and human alpha (leukocyte) interferon (13 patients). Acyclovir doses of 400 to 1200 mg/m2/dose and interferon doses of 2 to 40 X 10(4) units/kg/day were used. There was no consistent effect of treatment on the likelihood or duration of survival, titre of virus in paired lung specimens, or shedding of virus. However, four patients survived and four others had 2-log or greater decreases in the amount of virus in paired lung specimens, suggesting a possible effect on cytomegalovirus strains with increased sensitivity to these agents. Acyclovir treatment of cytomegalovirus infection may be more effective in patients with lesser degrees of immunosuppression, but was not effective in the treatment of marrow transplant patients with cytomegalovirus pneumonia. |
---|---|
AbstractList | Despite the lack of virus-specified thymidine kinase activity, human cytomegalovirus may be sensitive to acyclovir in vitro at concentrations between 10 and 25 mg/l. The inhibitory effect of acyclovir can be further increased by the presence of small amounts of human alpha or beta interferon. Twenty-one allogeneic marrow graft recipients with biopsy-proven cytomegalovirus pneumonia were treated with either high doses of acyclovir (eight patients) or the combination of acyclovir and human alpha (leukocyte) interferon (13 patients). Acyclovir doses of 400 to 1200 mg/m2/dose and interferon doses of 2 to 40 X 10(4) units/kg/day were used. There was no consistent effect of treatment on the likelihood or duration of survival, titre of virus in paired lung specimens, or shedding of virus. However, four patients survived and four others had 2-log or greater decreases in the amount of virus in paired lung specimens, suggesting a possible effect on cytomegalovirus strains with increased sensitivity to these agents. Acyclovir treatment of cytomegalovirus infection may be more effective in patients with lesser degrees of immunosuppression, but was not effective in the treatment of marrow transplant patients with cytomegalovirus pneumonia. |
Author | Springmeyer, S C McGuffin, R W Thomas, E D Meyers, J D Wade, J C |
Author_xml | – sequence: 1 givenname: J D surname: Meyers fullname: Meyers, J D – sequence: 2 givenname: J C surname: Wade fullname: Wade, J C – sequence: 3 givenname: R W surname: McGuffin fullname: McGuffin, R W – sequence: 4 givenname: S C surname: Springmeyer fullname: Springmeyer, S C – sequence: 5 givenname: E D surname: Thomas fullname: Thomas, E D |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/6313597$$D View this record in MEDLINE/PubMed |
BookMark | eNotj8tqwzAURLVISZO0P1Ao6Afs6GHJ1rINfUGgFNK1ka-vGgfLMpZd8N83bbOaYeAMM2uy6EKHhNxxlnJm5PZkYctFGqe-b8vHlBd8QVZMMpXkmZLXZB3jiTGmlS6WZKkll8rkK_JxOCKdItLgqIUZ2vDdDNSFgcI8Bo9f9i-ZIm06hzA2ofu1dDxjjfdTFyD4fgi-iVjTY4jjDblyto14e9EN-Xx-Ouxek_37y9vuYZ-A1HxMdMGYqZUxNpcuF-48jKNVIHIAboySXNSoqsoKXQvFM8eNQzRQgTWZE4XYkPv_3n6qPNZlPzTeDnN5uSZ-AIr8VA4 |
CitedBy_id | crossref_primary_10_1080_14656566_2016_1199684 crossref_primary_10_1016_0166_3542_85_90001_4 crossref_primary_10_1007_BF02014424 crossref_primary_10_1056_NEJM198506273122615 crossref_primary_10_1378_chest_94_5_949 crossref_primary_10_1016_0030_4220_87_90088_0 crossref_primary_10_1016_0749_2081_88_90052_6 crossref_primary_10_1016_S0399_077X_85_80302_4 crossref_primary_10_3109_inf_1985_17_suppl_47_01 crossref_primary_10_1111_j_1365_4362_1988_tb02417_x crossref_primary_10_1016_0190_9622_91_70049_8 crossref_primary_10_1016_S0399_077X_88_80398_6 crossref_primary_10_1111_j_1365_2710_1989_tb00256_x crossref_primary_10_1177_089719009000300106 crossref_primary_10_1016_S0399_077X_88_80102_1 crossref_primary_10_1111_j_1423_0410_1986_tb01990_x crossref_primary_10_1016_0166_3542_84_90011_1 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1093/jac/12.suppl_B.181 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 6313597 |
Genre | Controlled Clinical Trial Research Support, U.S. Gov't, P.H.S Review Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA 26966 – fundername: NCI NIH HHS grantid: CA 30924 – fundername: NCI NIH HHS grantid: CA 18029 |
GroupedDBID | --- -E4 .2P .GJ .I3 .XZ .ZR 0R~ 18M 1TH 29J 2WC 3O- 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6.Y 70D AABZA AACZT AAJKP AAJQQ AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAWDT AAWTL ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABPTD ABQLI ABQNK ABQTQ ABSAR ABSMQ ABWST ABXVV ABZBJ ACCCW ACFRR ACGFO ACGFS ACIWK ACMRT ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ACZBC ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEHUL AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFIYH AFOFC AFRAH AFSHK AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHXPO AI. AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS ASPBG ATGXG ATTQO AVNTJ AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM BZKNY C45 CAG CDBKE CGR COF CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECGQY ECM EE~ EIF EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HH5 HVGLF HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M49 MBLQV MHKGH ML0 N9A NGC NOMLY NOYVH NPM NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBS OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RHF RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCURE TEORI TJX TMA TR2 UCJ VH1 W8F WOQ X7H Y6R YAYTL YKOAZ YXANX ZGI ZKX ZXP ~91 ~A~ |
ID | FETCH-LOGICAL-c361t-68009d599a73f72f6561ea5c27cc1995312de5bba26d2514f19fee9cbca94f282 |
ISSN | 0305-7453 |
IngestDate | Sat Sep 28 08:37:58 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c361t-68009d599a73f72f6561ea5c27cc1995312de5bba26d2514f19fee9cbca94f282 |
PMID | 6313597 |
ParticipantIDs | pubmed_primary_6313597 |
PublicationCentury | 1900 |
PublicationDate | 1983-01-01 |
PublicationDateYYYYMMDD | 1983-01-01 |
PublicationDate_xml | – month: 01 year: 1983 text: 1983-01-01 day: 01 |
PublicationDecade | 1980 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of antimicrobial chemotherapy |
PublicationTitleAlternate | J Antimicrob Chemother |
PublicationYear | 1983 |
SSID | ssj0006568 |
Score | 1.3733501 |
SecondaryResourceType | review_article |
Snippet | Despite the lack of virus-specified thymidine kinase activity, human cytomegalovirus may be sensitive to acyclovir in vitro at concentrations between 10 and 25... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 181 |
SubjectTerms | Acyclovir - administration & dosage Acyclovir - adverse effects Acyclovir - therapeutic use Bone Marrow - drug effects Bone Marrow Transplantation Combined Modality Therapy Cytomegalovirus Infections - drug therapy Cytomegalovirus Infections - therapy Humans Immunosuppression Interferon Type I - administration & dosage Interferon Type I - therapeutic use Kidney - drug effects Leukemia - therapy Pneumonia, Viral - drug therapy Pneumonia, Viral - therapy Tremor - chemically induced |
Title | The use of acyclovir for cytomegalovirus infections in the immunocompromised host |
URI | https://www.ncbi.nlm.nih.gov/pubmed/6313597 |
Volume | 12 Suppl B |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bSyMxFA5VWfFFvOJlV_IgvtTRzi3TPLrLLlJQ3KWibyXJJNhlpyPaivXXe04SGq0XXF-GIemETL7TzMnhfN8hZJfbwlaMRVwwEWW6aEVt3Sqj0ighU1lkxibRnJyy4_Osc5lfNhr3T7KWRkN5oB5e5ZV8BlVoA1yRJfsfyE4GhQa4B3zhCgjD9cMYj1wwXqix-lff9W9s3qAaD-tKw-aPLaOQcuWyxtHX7CMvpMaE8psaoAa3E-keb7iqsPr9qm8lm1BO5EpXnrcVUoi1Lx7R7IQc4guv6dsJoVgklhnjdAv-NEN8x4YXKxzEhmP9A6Wj57XTJ9EIz8Jq5VGROQHgyQ6bNG2NUl9I2m2VsSvV8mILd_JWf4XCmEICnxB4sPf9YOrnAMR1ZWFlaZzmLsf33c4pWW3fM0NmijbujKcY5fFfcOYolJN38WQrmNkhzOvw-awWyBc_1tTJxHoo3SWy6PGiR85OlklDD1bI_IlPnlghe2dOpny8T7uBdXe7T_foWRAwH6-S39BNwa5obejErijYFZ2yKxrsCm4p2AR9YVcU7WqNnP_62f1xHPnSG5FKWTyMGJwjeJlzLorUFImBFYm1yFVSKIWk_jROSp1LKRJWgoecmZgbrbmSSvDMwDF-ncwO6oHeIFTCgbtMk0JjiLFExT0wG6V5LI3GIvSbZN2tWu_a6av0_HJuvdWxTRaC6X0lcwb-zvob-IZDuWOBfAQQ9mYz |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+use+of+acyclovir+for+cytomegalovirus+infections+in+the+immunocompromised+host&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=Meyers%2C+J+D&rft.au=Wade%2C+J+C&rft.au=McGuffin%2C+R+W&rft.au=Springmeyer%2C+S+C&rft.date=1983-01-01&rft.issn=0305-7453&rft.volume=12+Suppl+B&rft.spage=181&rft_id=info:doi/10.1093%2Fjac%2F12.suppl_B.181&rft_id=info%3Apmid%2F6313597&rft_id=info%3Apmid%2F6313597&rft.externalDocID=6313597 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7453&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7453&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7453&client=summon |